Market revenue in 2024 | USD 558.1 million |
Market revenue in 2030 | USD 871.1 million |
Growth rate | 7.6% (CAGR from 2025 to 2030) |
Largest segment | Topical |
Fastest growing segment | Transdermal |
Historical data | 2018 - 2023 |
Base year | 2024 |
Forecast period | 2025 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Topical, Transdermal |
Key market players worldwide | The Lubrizol Corp, Cambrex, Contract Pharmaceuticals Limited, Bora Pharmaceuticals, Ascendia Pharmaceuticals, Pierre Fabre, Piramal Pharma Solutions, DPT Laboratories, LGM Pharma, Pace Analytical Services |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to semi-solid dosage cdmo market will help companies and investors design strategic landscapes.
Topical was the largest segment with a revenue share of 95.2% in 2024. Horizon Databook has segmented the Sweden semi-solid dosage cdmo market based on topical, transdermal covering the revenue growth of each sub-segment from 2018 to 2030.
Horizon Databook provides a detailed overview of country-level data and insights on the Sweden semi-solid dosage cdmo market , including forecasts for subscribers. This country databook contains high-level insights into Sweden semi-solid dosage cdmo market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account